InsiderClue
← All stocks

Summit Therapeutics Inc.

SMMT Net buying
CIK 0001599298 #943 in the set updated 17 Sep 2026
Bought (120 mo)
$758.92M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$321.46K
$0.00 on a plan · $321.46K straight out of an exercise
Sold at will
$0.00
0 of 5 sales
Net
+$758.60M
+$758.92M against sales at will

By person

8 insiders · 48 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
DUGGAN ROBERT W
Co-Chief Executive Officer
$651.81M (9)
—
+$651.81M
599,708,353
75.18%
$7.87B
+786.4%
Zanganeh Mahkam
Co-Chief Executive Officer
$90.73M (17)
—
+$90.73M
574,404,693
72.00%
$7.54B
+10.4%
Xia Yu
Director
$10.00M (1)
—
+$10.00M
32,057,147
4.02%
$420.59M
+1.7%
Soni Manmeet Singh
COO and CFO
$5.72M (3)
—
+$5.72M
3,123,603
0.3916%
$40.98M
—
Dhingra Ankur
Chief Financial Officer
$660.56K (6)
—
+$660.56K
393,015
0.0493%
$5.16M
+881.6%
Powell David Jonathan
Chief Scientific Officer
—
$321.46K (5) scheduled
−$321.46K
0
0.0000%
$0.00
—
Anand Bhaskar
Chief Accounting Officer
—
—
—
159,751
0.0200%
$2.10M
+43.9%
Huber Jeff
Director
—
—
—
44,052
0.0055%
$577.96K
—

Individual transactions

7
Insider
Date
Role
Action
Shares
Price
Amount
DUGGAN ROBERT W
30 May 2025
Co-Chief Executive Officer
Exercised, kept
74,545
$2.64
$196.80K
Zanganeh Mahkam
30 May 2025
Co-Chief Executive Officer
Exercised, kept indirect
74,545
$2.64
$196.80K
DUGGAN ROBERT W
8 Apr 2025
Co-Chief Executive Officer
Exercised, kept
3,985,055
$1.58
$6.30M
Zanganeh Mahkam
8 Apr 2025
Co-Chief Executive Officer
Exercised, kept indirect
3,985,055
$1.58
$6.30M
Zanganeh Mahkam
3 Oct 2024
Co-Chief Executive Officer
Exercised, kept indirect
315,681
$1.58
$498.78K
Zanganeh Mahkam
11 Dec 2023
Chief Executive Officer
Exercised, kept indirect
315,681
$1.58
$498.78K
Zanganeh Mahkam
11 Dec 2023
Chief Executive Officer
Exercised, kept
489,814
$1.44
$705.33K
Show all 48 transactions →

What was left out

Form 4 filings counted 105
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 5
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 51,110,923
History held since 6 Oct 2020